Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG‐TR)

The JIPANG study is a randomized phase III study of pemetrexed/cisplatin (Pem/Cis) versus vinorelbine/cisplatin (Vnr/Cis) for completely resected stage II‐IIIA non‐squamous non‐small cell lung cancer (Ns‐NSCLC). This study did not meet the primary endpoint (recurrence‐free survival, RFS) but Pem/Cis...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Kazuko, Tsuboi, Masahiro, Kenmotsu, Hirotsugu, Yamanaka, Takeharu, Takahashi, Toshiaki, Goto, Koichi, Daga, Haruko, Ohira, Tatsuo, Ueno, Tsuyoshi, Aoki, Tadashi, Nakagawa, Kazuhiko, Yamazaki, Koji, Hosomi, Yukio, Kawaguchi, Koji, Okumura, Norihito, Takiguchi, Yuichi, Sekine, Akimasa, Haruki, Tomohiro, Yamamoto, Hiromasa, Sato, Yuki, Akamatsu, Hiroaki, Seto, Takashi, Saeki, Sho, Sugio, Kenji, Nishio, Makoto, Okabe, Kazunori, Yamamoto, Nobuyuki, Nishio, Kazuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780021/
https://www.ncbi.nlm.nih.gov/pubmed/33185928
http://dx.doi.org/10.1111/cas.14730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780021/
https://www.ncbi.nlm.nih.gov/pubmed/33185928
http://dx.doi.org/10.1111/cas.14730

Ejemplares similares